BBOT director granted 91,076 options at $9.59, 10-year term
Frank McCormick, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a stock option to purchase 91,076 shares of common stock with an exercise price of $9.59 per share.
Rhea-AI Filing Summary
Frank McCormick, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a stock option to purchase 91,076 shares of common stock with an exercise price of $9.59 per share. The option was reported with a transaction date of 08/26/2025 and an expiration date of 08/25/2035. Vesting is governed by a schedule that begins on a Vesting Commencement Date of 08/11/2025: a fractional portion vests on the date an S-8 registration is filed and becomes effective, then 1/48th vests monthly thereafter until fully vested on the fourth anniversary, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.
Positive
- Director alignment with shareholders through a time-based stock option grant tied to service
- Clear vesting schedule including initial vesting upon S-8 effectiveness and monthly vesting thereafter until full vesting
Negative
- Potential future dilution if and when the 91,076 options are exercised
Insights
TL;DR: Director option grant of 91,076 shares at $9.59, ten-year term, time-based vesting tied to S-8 registration.
The reported grant is a non-derivative stock option covering 91,076 shares with a $9.59 exercise price and a ten-year contractual life to 08/25/2035. Vesting requires an initial pro rata vest upon effectiveness of an S-8 registration and monthly vesting thereafter through the fourth anniversary of the 08/11/2025 vesting commencement date, subject to continued service. For investors, this is a typical equity-based compensation mechanism aligning a directors incentives with shareholder value over multi-year horizons; it does not itself change outstanding share count until exercised.
TL;DR: Time-based director award with S-8 filing condition; standard governance practice but requires monitoring of future filings.
The award structure conditions initial vesting on the effectiveness of a Form S-8 registration statement, which is explicitly referenced in the filing. That condition and the multi-year monthly vesting schedule are disclosed clearly and link continued vesting to the reporting persons continuous service. Governance stakeholders should note the contractual vesting triggers and the potential for future filing activity (S-8) to accelerate vesting milestones, as described in the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 91,076 | $0.00 | $0.00 |
Footnotes (1)
- F1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Form 4 and which company is affected (ticker)?
What security and amount were reported on the Form 4?
What is the exercise price and term of the option?
When does vesting begin and how is it scheduled?
When was the transaction and when was the Form 4 signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.
